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ABSTRACT
Objectives To report the impact of burosumab on patient- 
reported outcomes (PROs) and ambulatory function in 
adults with X- linked hypophosphataemia (XLH) through 96 
weeks.
Methods Adults diagnosed with XLH were randomised 
1:1 in a double- blinded trial to receive subcutaneous 
burosumab 1 mg/kg or placebo every 4 weeks for 24 
weeks (NCT02526160). Thereafter, all subjects received 
burosumab every 4 weeks until week 96. PROs were 
measured using the Western Ontario and the McMaster 
Universities Osteoarthritis Index (WOMAC), Brief Pain 
Inventory- Short Form (BPI- SF) and Brief Fatigue Inventory 
(BFI), and ambulatory function was measured with the 
6 min walk test (6MWT).
Results Subjects (N=134) were randomised to burosumab 
(n=68) or placebo (n=66) for 24 weeks. At baseline, subjects 
experienced pain, stiffness, and impaired physical and 
ambulatory function. At week 24, subjects receiving burosumab 
achieved statistically significant improvement in some BPI- SF 
scores, BFI worst fatigue (average and greatest) and WOMAC 
stiffness. At week 48, all WOMAC and BPI- SF scores achieved 
statistically significant improvement, with some WOMAC and 
BFI scores achieving meaningful and significant change from 
baseline. At week 96, all WOMAC, BPI- SF and BFI achieved 
statistically significant improvement, with selected scores in 
all measures also achieving meaningful change. Improvement 
in 6MWT distance and percent predicted were statistically 
significant at all time points from 24 weeks.
Conclusions Adults with XLH have substantial burden 
of disease as assessed by PROs and 6MWT. Burosumab 
treatment improved phosphate homoeostasis and was 
associated with a steady and consistent improvement in 
PROs and ambulatory function.
Trial registration number NCT02526160.
Key messages
What is already known about this subject?
 ► In a phase 3 trial, burosumab significantly increased 
serum phosphate concentrations compared with 
placebo over 24 weeks, with a sustained effect on 
phosphate homoeostasis over time, and significantly 
improved patient- reported outcomes (PROs) from 
baseline to 48 weeks.
What does this study add?
 ► We further characterise the cumulative symptom 
burden of X- linked hypophosphataemia (XLH), 
showing that adults with XLH experience substantial 
pain, stiffness, fatigue and impairment in physical 
and ambulatory function.
 ► Rapid and persistent improvements in phosphate 
homoeostasis with burosumab treatment are as-
sociated with a consistent reduction in the burden 
of disease associated with XLH, with statistically 
significant improvements from baseline in PROs 
and ambulatory function seen as early as week 24 
and at week 96, achieving meaningful change from 
baseline in some pain, stiffness and fatigue scores.
How might this impact on clinical practice or 
further developments?
 ► The sustained positive outcomes over time indicate 
that, despite the long- term cumulative complica-
tions and physical impairments associated with XLH, 
burosumab improves symptoms that are clinically 
meaningful to adults with XLH, suggesting a role for 
long- term use of burosumab in improving physical 
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INTRODUCTION
X- linked hypophosphataemia (XLH) is a rare, genetic, 
progressive, lifelong phosphate wasting disease caused by 
loss- of- function mutations in the PHEX gene (phosphate- 
regulating endopeptidase homologue, X- linked), which 
results in excess circulating levels of fibroblast growth 
factor 23 (FGF23).1 2 The resultant chronic hypophos-
phataemia and osteomalacia in combination with the 
irreversible skeletal deformities acquired in childhood 
are associated with morbidities that develop and progress 
in adulthood, including osteoarthritis, enthesopathies, 
fractures, pseudofractures and spinal stenosis,3–5 causing 
bone and joint pain, stiffness, impaired mobility and 
diminished physical function. These morbidities ulti-
mately decrease health- related quality of life, limit activ-
ities of daily living and have a negative psychosocial 
impact.5–10
Until recently, the only treatment for XLH has been 
conventional therapy with oral phosphate replacement 
combined with active vitamin D. Relief of bone pain and 
healing of pseudofractures has been described in a small 
number of cases in a non- interventional study.11 However, 
due to the lack of robust trial data evaluating the efficacy 
of treatment with conventional therapy in adults, along 
with the known risks of treatment, a frequent practice 
has been to treat all children but only treat symptom-
atic adults.12 In a multinational, online survey 49% of 
adults with XLH were being treated with oral phosphate 
and 64% with active vitamin D metabolites, with 47% 
receiving both.5
Burosumab is a fully human monoclonal antibody that 
binds to excess circulating FGF23 and directly inhibits 
its activity, thereby correcting the aberrant phosphate 
homoeostasis in adults with XLH. The efficacy of buro-
sumab has been demonstrated in a randomised, double- 
blind, placebo- controlled phase 3 trial with open- label 
extension in adults with XLH.13 14 The primary endpoint 
analysis demonstrated a statistically significant effect of 
burosumab relative to placebo in increasing serum phos-
phate concentrations from baseline to week 24.14 Results 
from the treatment continuation period with all subjects 
receiving burosumab demonstrated that the effect of 
burosumab to improve phosphate homoeostasis was 
sustained over 48 weeks.13
Reporting of patient- reported outcomes (PROs) 
and ambulatory function was limited to the three key 
secondary endpoints (Brief Pain Inventory- Short Form 
(BPI- SF) worst pain, Western Ontario and the McMaster 
Universities Osteoarthritis Index (WOMAC) physical 
function subscale, WOMAC stiffness subscale) and one 
exploratory endpoint (change from baseline in 6 min 
walk test (6MWT) distance walked) in the week 24 and 
week 48 analyses.13 14 Burosumab was associated with 
improvement in the four patient- relevant endpoints 
when compared with the placebo- treated group at week 
24, however, with Hochberg multiplicity adjustment, 
only the difference in reduction in WOMAC stiffness 
was significant between treatments (p=0.012).14 Portale 
et al
13 reported that in both groups, burosumab was asso-
ciated with clinically significant and sustained improve-
ment from baseline to week 48 in scores for the same four 
patient- relevant endpoints (p<0.001).
To extend the initial report of the impact of burosumab 
on PROs and ambulatory function in adults with XLH, 
we report a change from baseline analysis through week 
96 on a wider range of PRO endpoints, using WOMAC, 
BPI- SF, Brief Fatigue Inventory (BFI) and ambulatory 
function according to 6MWT, and assess if the change 
reaches XLH- specific meaningful change benchmarks.
METHODS
Design
The design of this international, randomised, double- 
blind, placebo- controlled phase 3 study (NCT02526160) 
has been reported elsewhere and is only briefly described 
here.13 14
Patient and public involvement
Data collected from adults with XLH via an online survey 
and through interviews provided insights that informed 
the decision of which PRO measures to include in the 
clinical trial.5 6 The XLH Network, a patient advocacy 
group, was consulted in the development of the survey 
questions. These data indicated that pain, stiffness and 
impaired physical function and mobility were substan-
tial issues for adults with XLH, and that the BPI- SF and 
WOMAC were appropriate to measure deficits. As a 
result, the decision was made for BPI- SF worst pain score, 
WOMAC stiffness and WOMAC physical function to be 
key secondary efficacy endpoints.
Focus groups, in collaboration with The XLH 
Network, were held with adults with XLH to solicit 
input regarding the proposed duration of the study, 
number of site visits required, travel requirements and 
perceived burden of the assessments to be performed. 
The XLH Network also distributed recruitment mate-
rials to their members to increase awareness of the 
study. The results of the study were presented by physi-
cian speakers to the patient community at The XLH 
Network events.
Participants
Full inclusion and exclusion criteria are available in 
Insogna et al.14 Major inclusion criteria were adults (18–65 
years old) with a confirmed diagnosis of XLH, biochem-
ical findings consistent with XLH, and the presence of 
skeletal pain attributed to XLH or osteomalacia. Major 
exclusion criteria included recent history of traumatic 
fracture or orthopaedic surgery. For adults receiving 
therapies affecting phosphate metabolism, these thera-
pies must have been stopped prior to enrolment. Subjects 
were characterised according to enthesopathies, osteoar-
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Treatment groups
Eligible subjects were randomised 1:1 to receive buro-
sumab (1.0 mg/kg) or placebo administered subcuta-
neously every 4 weeks for 24 weeks in a double- blinded 
trial. Thereafter, all subjects entered an open- label treat-
ment continuation period for a further 24 weeks and 
received burosumab (1.0 mg/kg every 4 weeks). Subjects 
continued to receive burosumab for an additional 48 
weeks during the open- label treatment extension period 
until week 96.
Subjects randomised to burosumab are referred to as 
the burosumab–burosumab group, and those randomised 
to placebo as the placebo–burosumab group. Subjects 
remained blinded to their original treatment assignment 
throughout the first 48 weeks of the study.
PROs and ambulatory function endpoints
The objective of the present analysis was to evaluate the 
effect of burosumab on physical function, stiffness, pain 
and fatigue (at week 24, 48 and 96; secondary endpoints), 
and ambulatory function (at week 24, 48 and 72; explor-
atory endpoint) compared with baseline.
The WOMAC index, BPI- SF and BFI were used for 
PRO assessments. The WOMAC index, completed 
at on- site study visits, is a self- reported questionnaire 
designed to assess pain, stiffness and physical function in 
subjects with osteoarthritis of the knee or hip, and has 
been validated in XLH.15 16 The BPI- SF is a self- reported, 
pain- specific questionnaire measuring pain severity and 
interference that has been validated in XLH.17 18 Subjects 
completed all BPI- SF items at the study visit on the day 
of treatment administration; additionally, subjects also 
completed the four BPI- SF pain severity items daily in a 
written diary to more fully characterise pain variability. 
The BFI is a self- reported, fatigue- specific questionnaire 
measuring fatigue severity and interference that has been 
validated in XLH.19 20 Subjects completed the three BFI 
fatigue severity items in a daily diary and completed the 
full instrument at the study visit. WOMAC, BPI- SF and 
BFI endpoints were prespecified, with the exceptions of 
WOMAC total score, BPI worst pain (greatest), BFI worst 
fatigue (greatest) and BFI fatigue interference, all of 
which were post hoc. Table 1 summarises how the score 
for each PRO instrument was determined in this anal-
ysis, including how to interpret XLH- specific meaningful 
change.21
The 6MWT, used to assess ambulatory function, was 
administered by a trained clinician in accordance with 
principles set out in the American Thoracic Society 
guidelines.22 Subjects were instructed to walk the length 
of a premeasured course for six consecutive minutes. 
The total distance walked was recorded in metres; the 
percent predicted value for the 6MWT was calculated 
using published normative data based on age, sex and 
height.23 Here, we report the prespecified endpoints of 
6MWT distance walked and 6MWT percent predicted for 
age and gender.
Statistical analysis
Analyses were conducted for all randomised subjects 
who received at least one dose of either placebo or buro-
sumab. Continuous variables are summarised using the 
mean (SD) and categorical variables using number and 
percentage of subjects. Baseline impairment is described 
at the item level for all PRO instruments, and the use 
and type of pain medication being taken at baseline was 
recorded in subjects’ pain medication diaries.
For the change from baseline analysis, secondary and 
exploratory endpoints were analysed at a significance 
level of 5% using a generalised estimating equations 
Table 1 Patient- reported instruments used in the clinical trial
Feature WOMAC15 BPI- SF18 BFI19
Number of items 24 15* 9
Response format 5- point scale: none, mild, 
moderate, severe, extreme
0–10 numerical rating scale  
(10 indicates worst pain severity/
interference)
0–10 numerical rating scale
(10 indicates worst fatigue 
severity/interference)






Worst pain (average) (n=1)†
Worst pain (greatest) (n=1)†
Pain severity (n=4)
Pain interference (n=7)
Worst fatigue (average) (n=1)‡




Recall period 48 hours 24 hours 24 hours











*BPI- SF has 15 items in total, 11 items contribute to the scores reported in this analysis.
†BPI- SF question 3 asks subjects to rate their pain at its worst in the last 24 hours on a scale of 0 (no pain) to 10 (pain as bad as you can imagine). 
This study reports worst pain (average score for question 3 over 8 days) and worst pain (greatest score for question 3 over 8 days).18 27 28
‡BFI question 3 asks subjects to rate their fatigue at its worst in the last 24 hours on a scale of 0 (no fatigue) to 10 (fatigue as bad as you can 
imagine). This study reports worst fatigue (average score over 8 days) and worst fatigue (greatest score over 8 days).19
§A guide for interpreting the mean in a group of subjects rather than a change in an individual.21
BFI, Brief Fatigue Inventory; BPI- SF, Brief Pain Inventory- Short Form; MCID, minimal clinically important difference; WOMAC, Western Ontario and 
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(GEE) repeated- measures analysis. Treatment visit and 
treatment- by- visit interaction were included as cate-
gorical variables. Baseline stratification was performed 
for BPI average pain (>6.0, ≤6.0). The GEE model 
was applied through week 96 for PRO endpoints and 
week 72 for 6MWT; the model included p value assess-
ment for within- group change from baseline. Data are 
presented as least squares mean (SE) change from 
baseline. Missing data were handled according to the 
guidelines for each of the three questionnaires and the 
6MWT. SAS V.9.4 or higher (SAS Institute) was used for 
statistical analyses.
RESULTS
In total, 163 subjects were screened, and 134 were 
enrolled and randomised to burosumab (n=68) or 
placebo (n=66), with 133 subjects completing the placebo- 
controlled period; 126 subjects (94.0%) completed week 
48 of the treatment continuation period and entered 
the open- label treatment extension period13; and 119 
subjects (88.8%) completed the treatment extension 
period (48–96 weeks). All 134 subjects were included in 
the present analysis of PROs and ambulatory function.
Mean (SE) exposure to burosumab was 771 (22) days 
(range 167–957) for the burosumab–burosumab group 
and 626 (19) days (range 165–844) in the placebo–buro-
sumab group.
Overall, the demographics were similar between treat-
ment groups, as well as between subjects who completed 
the treatment extension period (n=119) and the total 
cohort enrolled (N=134) (table 2).
Baseline impairment
At baseline, subjects reported impairment in WOMAC 
total, physical function, stiffness and pain scores (table 2). 
Subjects reported notable difficulty going down stairs 
(50.4% had severe/extreme impairment) and doing 
heavy household chores (56.0% (severe/extreme)) with 
stiffness after waking (59% (severe/extreme)) and pain 
when going up or down stairs (55.6% (severe/extreme)) 
(figure 1A).
Subjects reported pain and pain interference at base-
line, with most subjects (71.6%) having a baseline BPI- SF 
worst pain (average) score >6.0 (severe) (table 2). The 
BPI- SF pain interference score showed moderate disrup-
tion in activities of daily living due to pain; severe pain 
when walking, during general activity and during normal 
work completely interfered with daily life for 11.2%, 8.2% 
and 9.7% of subjects, respectively (figure 1B).
Subjects reported mean worst fatigue (average) 
score >6.0 at baseline (table 2). The greatest overall 
impact was reported for the BFI interference items 
of walking ability, normal work and enjoyment of life, 
with the highest fatigue interference scores observed in 
walking ability (8.3% reported complete interference 
with daily living) (figure 1C).
Mean 6MWT distance walked was approximately half of 
the predicted distance based on age and sex, indicating 
impaired ambulation at baseline (table 2).
Change from baseline
Subjects randomised to receive burosumab in the 
double- blind period had statistically significant improve-
ments from baseline WOMAC stiffness scores at week 24 
(p=0.007; figure 2C). At week 48, after the placebo group 
had been crossed over to receive burosumab for 24 weeks, 
the burosumab–burosumab and placebo–burosumab 
groups had significant improvements from baseline for 
all WOMAC scores (total score, figure 2A; physical func-
tion, figure 2B; stiffness, figure 2C and pain, figure 2D; all 
p<0.05); similarly at week 96, significant improvements 
from baseline were evident for all WOMAC scores (all 
p<0.05). Meaningful change was achieved for WOMAC 
stiffness in both treatment groups at weeks 48 and 96. 
For WOMAC physical function, meaningful change was 
achieved in the burosumab–burosumab group at week 
48 and in both treatment arms at week 96. Meaningful 
change (see table 1 for definition) was also achieved 
at week 96 in the burosumab–burosumab group for 
WOMAC total score and WOMAC pain.
Subjects randomised to burosumab had significant 
improvements from baseline at week 24 in BPI- SF 
worst pain (average) (p<0.001; figure 3A), BPI- SF worst 
pain (greatest) (p<0.001; figure 3B) and BPI- SF pain 
interference (p=0.05; figure 3C). At weeks 48 and 96, 
improvements from baseline were significant for the 
burosumab–burosumab and placebo–burosumab groups 
for all BPI- SF scores (figure 3A–C; all p<0.001). Mean-
ingful change was achieved for worst pain (greatest) in 
the placebo–burosumab group at week 48 and in both 
groups at week 96 (figure 3B). For pain interference, 
meaningful change was achieved in both treatment 
groups at weeks 48 and 96 (figure 3C).
Subjects randomised to burosumab had significant 
improvements from baseline at week 24 in BFI worst 
fatigue (average) (p=0.020; figure 4A) and BFI worst 
fatigue (greatest) (p=0.004; figure 4B). At week 48, 
improvements from baseline in worst fatigue (average 
and greatest) were significant for the burosumab–buro-
sumab and placebo–burosumab groups (both p<0.001; 
figure 4A and B); for fatigue interference and global 
fatigue, significant improvements were observed in 
the placebo–burosumab group at week 48 (all p<0.05; 
figure 4C and D). At week 96, significant improvement 
was observed for all fatigue parameters in both groups 
(all p<0.05). Meaningful change from baseline was 
achieved for BFI worst fatigue (greatest) at week 48 in 
the placebo–burosumab group and at week 96 in both 
groups.
Subjects randomised to burosumab had significant 
improvements from baseline in 6MWT distance walked 
(p=0.018; figure 5A) and percent predicted (p=0.021; 
figure 5B) at week 24. Once all subjects were receiving 
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both 6MWT distance walked and percent predicted were 
observed in the burosumab–burosumab and placebo–buro-
sumab groups (both p<0.05); statistical significance was 
also observed at week 72 for both treatment groups (both 
p<0.05).
DISCUSSION
In adults with XLH, further morbidities develop in 
addition to those that manifest in childhood, including 
osteoarthritis, enthesopathies, fractures, pseudofrac-
tures and spinal stenosis, which can diminish mobility, 
physical function and quality of life.5–10 In this extended 
analysis of a previously reported phase 3 trial of buro-
sumab in adults with XLH, we describe the high level 
of impairment at baseline and determine the impact of 
burosumab treatment on a wide range of PRO and ambu-
latory function endpoints through week 96 and assess 
clinical meaningfulness to provide a more complete 
Table 2 Patient baseline characteristics and patient- reported outcome and ambulatory function scores at baseline







  Mean (SD) 41.3 (11.6) 38.7 (12.8) 40.0 (12.2) 40.5 (12.2)
  Range 20.0–63.4 18.5–65.5 18.5–65.5 18.5–65.5
Female, n (%) 44 (64.7) 43 (65.2) 87 (64.9) 77 (64.7)
Geographic region, n (%)
  North America/Europe 58 (85.3) 58 (87.9) 116 (86.6) 101 (84.9)
  Asia 6 (8.8) 5 (7.6) 18 (13.4) 18 (15.1)
Height (cm), mean (SD)† 152.2 (9.5) 152.7 (11.8) 152.4 (10.7) 152.1 (11.0)
BMI, mean (SD)† 30.0 (7.5) 30.6 (7.8) 30.3 (7.6) 30.6 (7.8)
Serum phosphate (mg/dL), mean (SD) 2.0 (0.3) 1.9 (0.3) 2.0 (0.3) 2.0 (0.3)
WOMAC, mean (SD)
  Total score 51.8 (18.3) 46.2 (17.7) 49.1 (18.2) 49.2 (18.4)
  Physical functioning 50.8 (19.7) 43.9 (19.9) 47.4 (20.0) 47.6 (20.3)
  Stiffness 64.7 (20.3) 61.4 (20.8) 63.1 (20.5) 62.6 (20.8)
  Pain 50.7 (18.0) 48.0 (15.5) 49.3 (16.8) 49.3 (16.8)
Pain scores
BPI- SF worst pain (average)
  Mean (SD) 6.8 (1.3) 6.5 (1.4) 6.7 (1.4) 6.7 (1.4)
  ≤6.0, n (%) 15 (22.1) 23 (34.8) 38 (28.4) 33 (27.7)
  >6.0, n (%) 53 (77.9) 43 (65.2) 96 (71.6) 86 (72.3)
BPI- SF worst pain (greatest)
  Mean (SD) 8.1 (1.2) 8.0 (1.5) 8.0 (1.3) 8.0 (1.3)
BPI- SF pain interference, mean (SD) 5.2 (2.2) 4.8 (2.2) 5.0 (2.2) 5.1 (2.2)
Any pain medication use, n (%) 47 (69.1) 44 (66.7) 91 (67.9) 81 (68.1)
Opioid use, n (%) 17 (25.0) 13 (19.7) 30 (22.4) 26 (21.8)
Fatigue scores, mean (SD)
  BFI global fatigue 5.4 (2.0) 4.9 (1.9) 5.1 (2.0) 5.1 (2.0)
  BFI worst fatigue (average) 6.9 (1.7) 6.7 (1.5) 6.8 (1.6) 6.9 (1.6)
  BFI worst fatigue (greatest) 8.2 (1.4) 8.2 (1.3) 8.2 (1.3) 8.2 (1.4)
  BFI fatigue interference 5.0 (2.3) 4.5 (2.3) 4.8 (2.3) 4.8 (2.3)
Ambulatory function, mean (SD)
  6MWT distance walked, m 356.8 (109.5) 367.4 (103.4) 362.0 (106.3) 358.9 (108.3)
  6MWT percentage predicted distance, % 51.4 (15.8) 52.3 (14.9) 51.8 (15.3) 51.5 (15.7)
WOMAC range, 0–100, where 0 represents best health; BPI- SF range, 0–10, with 10 indicating worst pain; BFI range, 0–10, with 10 indicating worst 
fatigue.
*Subjects who completed the 96- week study extension period.
†Height and BMI were not recorded at baseline for one participant in each group.
6MWT, 6 min walk test; BFI, Brief Fatigue Inventory; BMI, body mass index; BPI- SF, Brief Pain Inventory- Short Form; WOMAC, Western Ontario and 
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Figure 1 Proportion of adults reporting (A) WOMAC, (B) BPI- SF and (C) BFI item level scores at baseline (N=134). Interference 
of pain on walking ability and normal work were not recorded at baseline for one participant in each group. BFI, Brief Fatigue 
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evaluation of the benefit of burosumab for adults with 
XLH.
Due to the inclusion criteria requiring a BPI- SF worst 
pain score ≥4, the baseline pain observed in the current 
study is consistent with or higher than that reported in 
populations of adults with XLH.5 7 8 In an online survey 
of 232 adults with XLH,5 the mean BPI- SF worst pain 
score was 5.1, indicating pain of moderate severity, with a 
higher worse pain score of 5.6 for adults who reported a 
history of fracture. Furthermore, 67% of adults reported 
using pain medication at least once a week and 21% 
reported prescription pain medication use.5 The mean 
WOMAC pain score at baseline in the present study was 
greater than that reported in people with rheumatoid 
arthritis in a population- based survey (49.3 vs 14.9).24 
These data collectively demonstrate that, with current 
Figure 2 Change from baseline in WOMAC (A) total score, and (B) physical function, (C) stiffness and (D) pain scores (N=134). 
Data show LS mean (±SE); lower scores indicate better health. *p<0.05 for LS mean change from baseline. †Indicates the 
minimal clinically important differences from baseline (≥−10.0 total score, ≥−8.0 physical function, ≥−10.0 stiffness, ≥−11.0 
pain, shown by the pale grey horizontal line). LS, least squares; WOMAC, Western Ontario and the McMaster Universities 
Osteoarthritis.
Figure 3 Change from baseline in BPI- SF (A) worst pain (average), (B) worst pain (greatest) and (C) pain interference scores 
(N=134). Data show LS mean (±SE); lower scores indicate lower pain severity and less pain interference. *p<0.05 for LS mean 
change from baseline. †Indicates minimal clinically important differences from baseline (≥−1.72 worst pain (average, greatest), 
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treatment options, pain is a major issue in adults with 
XLH.
With burosumab treatment, significant improvement 
from baseline was seen in pain scores as early as week 
24; meaningful change was observed at week 48 for pain 
interference and at week 96 for worst pain (greatest) 
and pain interference. The mean age of subjects in this 
study was 40 years and most had XLH- related muscu-
loskeletal morbidities causing chronic pain, including 
osteomalacia, osteoarthritis, pseudofractures, fractures 
and enthesopathies.13 14 While pain may be expected 
to improve with burosumab treatment with the healing 
of osteomalacia and fractures, some causes of pain may 
not be amenable to therapies that target FGF23 and thus 
may not correct the aberrant phosphate homoeostasis in 
adults with XLH. Osteophytes, osteoarthritis and enthe-
sopathy are structural changes that are unlikely to be 
affected by treatment with burosumab, thus resulting in 
residual pain.25 However, these data indicate that adults 
with pain due to XLH benefit from burosumab treat-
ment, irrespective of their symptoms and baseline radio-
graphic damage, although within the confines of the 
study inclusion/exclusion criteria requiring the presence 
of pain and in a population with a mean age of 40 years.
Pain and stiffness associated with XLH can cause 
significant disability in adults with XLH.5 The baseline 
mean WOMAC stiffness score indicates that adults in this 
trial experience substantial stiffness compared with the 
general population.5 With burosumab, WOMAC stiffness 
Figure 4 Change from baseline in BFI (A) worst fatigue (average), (B) worst fatigue (greatest), (C) global fatigue and (D) 
fatigue interference scores (N=134). Data show LS mean (±SE); lower scores indicate lower fatigue severity and less fatigue 
interference. *p<0.05 for LS mean change from baseline. †Indicates the minimal clinically important difference from baseline 
(≥−1.5 worst fatigue (average, greatest), ≥−1.2 global fatigue, ≥−1.2 fatigue interference, shown by the pale grey horizontal line). 
BFI, Brief Fatigue Inventory; LS, least squares.
Figure 5 Change from baseline in 6MWT (A) distance 
walked (metres) and (B) percentage predicted (%) (n=132). 
Data show LS mean (±SE); higher scores indicate better 
ambulatory function. *p<0.05 for LS mean change from 
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showed significant improvement from baseline as early 
as week 24. Importantly, meaningful improvement was 
observed with burosumab at week 48 and at week 96.
The improvements in PROs observed through to 96 
weeks highlight the potential benefits of continued 
burosumab treatment over time. Despite the long- term 
cumulative complications and physical impairments, 
maintenance of treatment with burosumab improves 
symptoms that are clinically meaningful to adults with 
XLH. This is the first randomised placebo- controlled 
trial to show therapeutic improvement of patient- 
relevant musculoskeletal symptoms in adults with XLH 
over 96 weeks using PRO endpoints that have not been 
previously reported and with an evaluation of whether 
observed change from baseline achieved XLH- specific 
minimal clinically important differences (MCIDs).
This present analysis has several limitations. The 
subjects of the trial were adults with XLH who were symp-
tomatic despite prior exposure to conventional therapy. 
After 24 weeks, burosumab treatment was given open 
label to all subjects; however, subjects and investigators 
remained blinded to the original treatment assignments 
until the week 48 analysis was completed to minimise 
bias. Furthermore, the trial was designed vs placebo 
to week 24; therefore, analysis of this trial is unable to 
provide data on the efficacy of conventional therapy on 
patient- relevant outcomes.
In the trial, there was no radiographical follow- up for 
the subjects, and as such it is not possible to correlate 
the PRO changes with some of the potential structural 
changes.
Subjects were required to maintain a stable dose and 
schedule of pain medication up to week 24, after which 
time pain medication could be adjusted as necessary. 
Although data were collected on change in pain medica-
tion use at 24–48 weeks, the analysis and interpretation 
of the use of pain medication in a clinical trial and over 
a short time frame is challenging and contrived. The util-
isation of pain medication with burosumab treatment 
should be investigated in the future using real- world 
evidence from observational studies.26
Finally, although XLH- specific MCIDs have been calcu-
lated and published,16 17 20 these are preliminary, and 
additional work is required to derive MCIDs in larger 
samples of subjects with XLH and XLH- specific MCIDs 
for 6MWT distance.
In conclusion, adults with XLH experience substantial 
burden of disease as a result of musculoskeletal morbid-
ities that have developed despite current treatment 
options, causing symptoms of pain, stiffness and fatigue, 
as well as impairment in physical and ambulatory func-
tion. Statistically significant improvements from baseline 
in PROs and ambulatory function were observed early 
and persisted up to week 96 with burosumab treatment, 
with predefined meaningful changes observed in pain, 
stiffness and fatigue. Together, these findings demon-
strate that the rapid and sustained improvement in phos-
phate homoeostasis induced by burosumab treatment 
is associated with sustained reduction in the substantial 
burden of disease that has accumulated over the lifetime 
in adults with musculoskeletal pain related to XLH and 
suggest that long- term use of burosumab has a role in 
improving these outcomes in adults with XLH.
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